

BEST AVAILABLE COPY

European Patent Office  
Erhardtstraße 27  
D-80298 München 2  
Germany

Re: Opposition proceedings  
concerning EP-B-0125023  
of Genentech, Inc. et al.

DECLARATION OF LEON R. LYLE, Ph.D.

I, Leon R. Lyle, Ph.D. declare and say as follows: -

1. I have received B.A. and M.A. degrees in Biology and Microbiology from Drake University, Des Moines, Iowa, U.S.A. and a Ph.D. in Microbiology from Montana State University, Bozeman, Montana, U.S.A., and hold the position of Director, Technology Planning at Mallinckrodt Medical, Inc., St. Louis, Missouri, U.S.A. My Curriculum Vitae is attached hereto as Exhibit "A" and forms part of this Declaration.

2. I have no association whatsoever with Genentech, Inc., South San Francisco, California (other than as custodian of a few Genentech shares under the Uniform Gift to Minors Act), or the City of Hope, Duarte, California, which, I was informed, are the joint owners of the above-identified European patent.

3. I attended the Ninth Annual Meeting of the Clinical Ligand Assay Society which was held on March 13-17, 1983 in the Franklin Plaza Hotel, Philadelphia, U.S.A. The meeting had about 200-250 participants, and the oral and poster presentations embraced a variety of topics from the fields of analytical and diagnostic assays and antibody technology. The meeting, just as other meetings of the Clinical Ligand Assay Society, was not followed by the publication of a conference book or proceedings. At the time of the meeting the organizers provided the participants with a Syllabus, which contained those presentations by invited

speakers and those abstracts which had been submitted sufficiently in advance of the meeting for their printing, binding, and shipment to have taken place.

4. In and around 1983 I was actively involved in research pertaining to the production of monoclonal antibodies by hybridoma technology. At a breakfast roundtable of the 1983 Ligand Assay Society meeting I delivered a short presentation entitled "Practical Problems in the Production of Monoclonal Antibodies" with the declared purpose of facilitating the exchange of non-proprietary information among people responsible for the operation of hybridoma laboratories. A copy of the Abstract of this presentation along with the front pages and the author's index of the Syllabus of the Ninth Annual Meeting, in which it was published, is attached as Exhibit "B".


5. Because I had, and still have, a keen interest in antibody technology, I remember that the recipients of the 1983 Award (sponsored by Mallinckrodt, Inc., my employer) were Dr. Köhler and Dr. Milstein, who were first to develop the hybridoma method for the production of monoclonal antibodies. I remember that, to my disappointment if not necessarily to my surprise, both Dr. Köhler and Dr. Milstein were unable to attend the meeting. Instead, Dr. Marc Shulman accepted the Award and delivered the Mallinckrodt Award Lecture on their behalf. No written record was made available with respect to Marc Shulman's lecture at or after the meeting, including the Syllabus. This is apparent from the author's index submitted as part of Exhibit "B", which does not include Dr. Shulman's name. Therefore, there is nothing on which one can rely except one's own recollection or notes as to the content of Dr. Shulman's lecture.

6. It is my recollection that in his lecture, Dr. Shulman provided an overview of monoclonal antibodies and monoclonal antibody technology. Nothing in Dr. Shulman's lecture struck me as new revelations. I remember the lecture as being of general, review-type nature, which did not contain information that would have exceeded public knowledge at the time. I do not recall any

3

discussion of methods of recombinant DNA technology for the production of antibodies. I do not recall any discussion of chimeric antibodies or chimeric antibody technology. Specifically, I have absolutely no recollection of any mention of the replacement of an immunoglobulin gamma chain constant region by another constant region to alter the immunoglobulin's cytolytic activity, although the effector functions of the different subclasses of mouse IgG's may have been discussed. I have no recollection whatsoever of any discussion of substituting the constant region of a human antibody for the constant region of a mouse antibody to produce an immunoglobulin molecule which would be superior in human therapy.

7. I declare that the foregoing is true and correct to the best of my information and belief, and that this declaration was executed on this 9th day of August, 1994, St. Louis, Missouri.

  
\_\_\_\_\_  
Leon R. Lyle, Ph.D.  
Director, Technology Planning

Exh A

## CURRICULUM VITAE

**NAME:** Leon R. Lyle

**SOCIAL SECURITY NUMBER:** 480-48-1714

**AGE (Date of Birth):** 52 (11/28/41)

**PLACE OF BIRTH:** Ottumwa, Iowa (USA)

**MARITAL STATUS:** Married

**Spouse:** Mary Jane Lyle  
                  Assistant U.S. Attorney  
                  US Attorney's Office - St. Louis

**Children:** Elizabeth, age 17  
                  Dan, age 14

**OFFICE:** Mallinckrodt Medical, Inc.  
                  675 McDonnell Blvd.  
                  P.O. Box 5840  
                  St. Louis, Missouri 63134  
                  (314) 895-2352  
                  (314) 895-8992 (FAX)

**HOME:** 1319 Webster Path Drive  
                  Webster Groves, Missouri 63119  
                  (314) 968-8029

**EDUCATION:**

1963 B.A.	Biology, Drake University, Des Moines, Iowa
1967 M.A.	Microbiology, Drake University Des Moines, Iowa
1969 Ph.D.	Immunology and Microbiology Montana State University Bozeman, Montana

1970-1973      NIAID Post-Doctoral Fellow  
Washington University School of Medicine  
St. Louis, Missouri  
Cellular Immunology. Research dealt with  
mechanisms of antigen recognition and  
lymphocyte transformation, Immunology  
Department, Dr. Charles W. Parker

**HONORS:**

1968      Received Montana State University Institutional Phi  
Sigma Award for "Outstanding Achievement as a  
Graduate Student."

1969      Sigma Xi - elected to Associate Membership

1981      President's Award for Technical Innovation,  
Mallinckrodt, Inc.

**MEMBERSHIPS:**

American Association of Immunologists  
American Society for Microbiology  
American Association for Clinical Chemistry  
American Association for the Advancement of Science  
Association of University Technology Managers  
Society of Nuclear Medicine

**WORK EXPERIENCE:**

1991- Current

Director, Technology Planning

Responsible for the identification and development of new technical and business opportunities in Radiology, Cardiology, Nuclear Medicine, Oncology, Anesthesiology and Critical Care. Development and Administration of Mallinckrodt Medical's extramural research programs with universities. Primary personal technical focus is on chemoattractant cytokines involved in inflammation.

1985 - 1991

Associate Director, Immunoassay R&D,  
Mallinckrodt, Inc.

Responsible for the Hybridoma Sciences Section and R&D, Europe on a technical/functional basis. Overall responsibility for R&D activities in in vitro diagnostics in U.S. and Europe. Responsible for coordination with Japan In Vitro R&D. Experienced also in regulatory matters concerning in vitro immunodiagnostics for both human and veterinary applications.

1984 - 1985

Assistant Director, Hybridoma Sciences R&D,  
Mallinckrodt, Inc.

Responsible for management of the Hybridoma Section, general cell culture, monoclonal antibody based assay development efforts and coordination with two other International R&D facilities in in vitro diagnostics. Group has developed numerous high affinity antibodies which are being utilized in commercial products in Europe and Japan.

1982-1984

Research Manager, Hybridoma Sciences R&D,  
Mallinckrodt, Inc.

In 1982, I requested the assignment of further accelerating the hybridoma program. Developed capital projects for additional laboratory space and strategic plan. Recruited and trained personnel. Group was very efficient and produced high quality monoclonal antibodies to numerous analytes. Group responsible for support of production and International R&D projects. Also responsible for liaison function with and monitoring progress of a large cooperative hybridoma effort with a local medical school. Developed R&D, marketing, and advertising strategy for the antibodies coming from the program and implemented. All products marketed on schedule. This project was cited by management as an "example of perfect project execution".

1980-1982

Assistant Director, Immunoassay Section,  
Mallinckrodt, Inc.

Overall responsibility for the Department, 5 Ph.D.'s and 13 staff scientists. Responsible for new product planning, budget, general administration, safety and GLP compliance. Responsible for product improvement, production transfer and production trouble shooting. Group developed improved  $\beta$ hCG test which was very favorably reviewed in the clinical literature. Initiated microbiology program. Led the project team responsible for the introduction of Dirotest™, the first USDA licensed ELISA test for dog heartworm. Early in 1980, was given the responsibility of bringing hybridoma technology into the Company. This was accomplished. Developed high affinity monoclonal antibodies to T4 which were utilized in the SPACTM solid support system and in a free T4 test currently marketed in Europe.

1975-1980

Group Leader, Mallinckrodt, Inc.

Supervised 2 Ph.D.'s and 4 staff scientists in product development. Group developed RIA-Quant™ hCG assay, and a liquid hTSH assay. Personally handled development of iodination procedures for these materials and design of stability studies used by the Department. Assisted in preparation of 510k submissions. Group also developed RIA-Mat™ T4 and T3 tests. These products were converted to lyophilized products and then to solid support tests, the SPACT™, Digoxin, T3, T4 and T3U (uptake). Group also developed Folate and B12 tests (not marketed).

1973-1975

Radiopharmaceutical Chemist, Mallinckrodt, Inc.

Primary responsibilities involved product development and transfer to operations.  
Developed RIA-Mat™ Digoxin test.

#### APPOINTMENTS:

1981-1984

Immunology Devices Advisory Panel Office of Medical Devices, FDA (Industrial Representative)

1984-1988

(Reappointed)  
Term ended February 29, 1988

1987

Scientific Program Chairman  
Clinical Ligand Assay Society National Meeting  
St. Louis, Missouri



**SELECTED  
BIBLIOGRAPHY:**

- Lyle, L.R. and Parker, C.W., "Cyclic adenosine 3',5'-monophosphate response to oncanavalin A in human lymphocytes. Evidence that the response involves specific carbohydrate receptors on the cell surface," Biochemistry **13**: 5415-5420 (1974).
- Lyle, L.R. and Parker, C.W., "New approaches to immunosuppression," Fed. Proc. **33**: 1889-1893 (1974).
- Lyle, L.R., "Production and Applications of Monoclonal Antibodies," Medical Device & Diagnostic Industry **4**(6): 40-44 (1982).
- Scott, M.G., W.H. Lin, L.R. Lyle, P.R. Atkinson, J.E. Seeley and E. Markoff. Monoclonal Antibodies Specific For Non-Glycosylated Porcine Prolactin and for Pituitary Porcine Prolactin. B&BRC, 151, 1427-1433 (1988).
- Scott, M.G., G.C. Curca, J.R. Petersen, L.R. Lyle, B.D. Burleigh and W.H. Daughaday. Specific Immunoradiometric Assay of Insulin-Like Growth Factor I with use of Monoclonal Antibodies. Clin Chem **33**: 2019-2023 (1987), Also, Clin Chem **33**: 893 (1987).
- Miller, K.M., J.H. Wilbe, J.R. Coveney, L.R. Lyle, P.E. Gargan, V.A. Ploplis and A.R. Fritzberg. Imaging Thrombin in a Rabbit Jugular Vein with Technetium-99M Mlt-1 Monoclonal Antibody. J. Nuc. Med. **31**: 747 (1990), Also, J Labelled Compd Radiopharm **30**: 322 (1991), Fibrinolysis **4**: 39 (1990), K.M. Miller and L.R. Lyle USP 5,080,883 January 14, 1992.
- Barnhart, J.L., M. Harada, L.R. Lyle and C.A. Savaris. Immunologic Reactions of Human Recipients to Repeated Exposures to Albunex Microspheres, Investigative Radiology **26**: S198-200 (1991).
- Majacha, R.E., J.M. Reno, R.P. Friedland, C. Vanhaight, L.R. Lyle and C.A. Marotta. Development of a Monoclonal Antibody Specific for Beta-A4 Amyloid in Alzheimer's Disease Brain for Application to In-Vivo Imaging of Amyloid Angiopathy. J. Nucl. Med. **33**: 2184-2189 (1992). Also, Neurology **41**: 156 (1991), J. Cerebral Blood Flow and Metabolism **11**: S186 (1991).

Page 7  
Leon R. Lyle

Hay, R.V., R.S. Skinner, O.C. Newman, S.L. Kunkel, L.R. Lyle, B. Shapiro and M.D. Gross. Nuclear Imaging of Acute Inflammatory Lesions with Recombinant Human Interleukin-8. Presented, Soc. Nuc. Med. Meeting June 11, 1993.


# Philadelphia

celebrates

# CLAS

SYLLABUS

Fifth Annual  
Meeting & Exhibit  
Franklin Plaza Hotel  
Philadelphia, PA  
March 13-17, 1983



12

PRACTICAL PROBLEMS IN THE PRODUCTION OF MONOCLONAL ANTI-  
BODIES, Leon Lyle, Ph.D., Mallinckrodt Diagnostics, St.  
Louis, MO

The objective of the meeting is to provide a forum for the exchange of non-proprietary information among people responsible for the operation of hybridoma laboratories. The discussion will address technical issues, problems and their resolution, and day-to-day laboratory operations. The topics will include: laboratory planning and start-up, fine points of technique, high volume antibody production and Regulatory considerations.

The goal is that the participants will exchange information on these points indicating what methods work best for them, specific problems they have encountered, how they dealt with them and what steps they have taken to prevent reoccurrence. Participants should be willing to act as resources to one another, both for these and subsequent discussions.

SYLLABUS

NINTH ANNUAL MEETING  
CLINICAL LIGAND ASSAY SOCIETY  
MARCH 13-17, 1983  
PHILADELPHIA, PENNSYLVANIA

Barry J. Burns, Ph.D.  
SYLLABUS EDITOR

Available from:

Clinical Ligand Assay Society, Inc.  
P.O. Box 67  
Wayne, MI 48184  
313-722-6290

© Copyrighted by Clinical Ligand Assay Society, Inc.  
All rights reserved.  
Contents cannot be reproduced without permission.

---

## Foreword

Traditionally, the Annual Meeting Syllabus contains the presentations by invited speakers and workshop faculty as well as the submitted abstracts, and is made available at the time of the meeting. This objective annually presents a challenge to the Syllabus Editor in terms of obtaining the articles sufficiently in advance of the meeting so that printing, binding, and shipment can be achieved. This year has proved to be no exception, especially since the meeting this year is almost two months earlier than it has been in the past.

Several of our invited speakers were unable to submit manuscripts within our time constraints due to their own heavy work schedules. Nevertheless, the volume contains excellent papers from the majority of our invited speakers, and we believe this year's Syllabus is a worthwhile reference book. The Editor appreciated the fine effort of the invited speakers who did submit manuscripts in meeting the extraordinary time limitations asked of them.

In addition the Editor acknowledges the extra effort made by all committee members in bringing about this fine well rounded program in so short a period of time.

Barry J. Burns

Adkinson, N.F., Jr.	212	Golner, B.B.	218
Alexander, T.J.	212	Gordesky, S.	179
Ashkar, F.S.	187	Green, B.J.	214
Bailey, A.	215	Hager, C.B.	210
Bagul, C.	210	Hakim-Afzal, K.	216
Bach, L.	217	Hamilton, R.G.	185, 202, 212
Barbieri, E.J.	183	Hartfield, D.L.	214
Berry, A.J.	216	Hawker, C.D.	180
Blankstein, L.	213, 214	Holinsky, J.	215
Bookout, J.B.	212, 217	Hurwitz, J.A.	210
Boyle, W.	218		
Bradley, L.A.	211	Ip, S.	28
Bremmer, W.S.	193, 199		
Caggiano, D.	214	Jacob, R.A.	218
Carey, R.N.	205	Jacobs, E.	213
Carter, J.H.	201, 215	Kaase, K.	199, 200
Caughey, I.	214	Kliman, B.	210, 211
Cernosek, S.F., Jr.	199, 200	Kocon, R.	210
Chalif, D.J.	219	Kowalczyk, R.S.	202
Chase, G.D.	199	Kurkjian, D.	215
Clifford, V.	210	Kurtz, B.	216
Compton, A.A.	218		
Conlon, D.	213	LaFrance, A.	215
Cooper, P.R.	219	Leddy, M.	211
Daniels, A.	162, 172	Levinson, S.	213
Demers, L.M.	204	Lin, W.H.	211
Deutsch, S.	160, 170	Lipset, J.S.	212
Deyken, D.	38	Lipsett, M.S.	1
DiGregorio, J.	159	Longley, W.	215
DiNuccio, J.M.	218	Lyle, L.	167
Doss, R.C.	214		
Drew, H.M.	217	MacLaughlin, R.A.	211
Ebersole, R.C.	196	Marcus, M.	182
Ekins, R.	7, 82	Marsden, D.S.	199
Ellis, J.	213	Mayo, M.H.	217
El-Negeh, N.	216	McCann D.S.	175, 218
Engel, R.H.	192	McCormick, W.M.	212
Famulare, A.J.	210	Mehra, M.	216
Feil, P.	189	Michaelwicz, H.	216
Fordice, M.W.	215	Monroe, L.	199
Franco, E.L.	211	Moore, R.J.	219
Fuccillo, D.A.	212	Muckerheide, M.M.	213
Gahan, J.	146		
Garcia, M.M.	199, 200	Narang, R.	216
Giering, L.	201	Ng, R.N.	211
Golden, D.	202	Nickoloff, E.L.	206
Goldman, J.	213	Nino, H.V.	191
Goldman, J.M.	217	Nusynowitz, M.	157
		O' Boyle, E.	216
		O' Neill, E.M.	211
		Olson, D.R.	210, 217



Patel, D.	216
Parsons, G.	214
Pegg, J.	190
Perlstein, M.T.	124, 178, 199
Petersen, J.R.	211
Pippenger, C.E.	203, 204
Polsky-Cynkin, R.	214
Previte, C.	212
Ramsey, J.F.	219
Rose, N.R.	26
Reisner, H.M.	211
Rigg, G.	218
Rosenbaum, A.	211
Rule, A.H.	216
Sakelaris, J.	210
Sampson, B.	214
Schatallius, D.	203
Schatzberg, A.	211
Schilling, R.F.	213
Schneider, N.	204
Shaw, L.M.	197
Sickel, M.	215
Slawecki, R.A.	217
Slonicki, A.	215
Smith, M.J.	174
Sockol, C.	215
Stalcup, S.A.	212
Statland, B.E.	211
Standefer, J.E.	72
Stearns, F.M.	216
Steele, B.W.	68
Stevens, R.	214
Strong, J.E.	201
Sun, M.	214
Tontala, F.J.	210
Toro, G.	211
Usategui-Gomez, M.	162, 194
Walsh, P.	201
Wasserman, P.	217
Wheeler, M.F.	217
Whitworth, A.	214
Witherspoon, L.R.	157, 168, 199
Wittliff, J.L.	203
Wood, A.	214
Woodhead, S.	67, 204
Worthy, T.E.	210, 215
Yuan, A.S.	210
Zurawski, V.R., Jr.	6, 176

European Patent Office  
Erhardstrasse 27  
D-80331 Munich  
Germany

Subject: Opposition to European Patent EP 1 120 694 B1  
Appl. No.: 84 301 996.9

Patent Owner: Celltech Limited  
244-250 Bath Road  
Slough, Berkshire, SL1 4DY (GB)

Title: PROCESSES FOR THE PRODUCTION OF MULTICHAIN  
POLYPEPTIDES OR PROTEINS

- and -

Subject: Opposition to European Patent EP 0 125 023 B1  
Appl. No.: 84 302 368.0

Patent Owner: Genentech, Inc.  
South San Francisco, California  
United States of America

Title: RECOMBINANT IMMUNOGLOBULIN PREPARATIONS,  
METHODS FOR THEIR PREPARATION, DNA SEQUENCES,  
EXPRESSION VECTORS AND RECOMBINANT HOST CELLS  
THEREFOR

## **DECLARATION OF MARC J. SHULMAN**

I, MARC J. SHULMAN, hereby declare:

1. I am a Professor of Immunology and Molecular and Medical Genetics in the Faculty of Medicine, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada, M5S 1A8.
2. I began conducting research in the immunoglobulin (Ig) field in the mid 1970's at the Basel Institute for Immunology. While there, I worked primarily with Dr.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**